<DOC>
	<DOCNO>NCT01495676</DOCNO>
	<brief_summary>If radical cystectomy remain standard care muscle invasive bladder cancer , consequence surgical procedure often harsh . Over past year , concurrent chemo-radiotherapy imposed alternative treatment . Published data concomitant radiochemotherapy ( radiotherapy/cisplatin radiotherapy/cisplatin/5-fluorouracil combination ) show local control rate bladder preservation 5 year range 40 % 65 % accord disease stage , overall survival probability range 40 % 50 % 5 year . In order improve local systemic prognosis , evaluation chemotherapy agent higher radiosensitizing effect , gemcitabine , justified . Gemcitabine possess anti-cancer activity urothelial disease synergetic activity cisplatin . The investigator complete monocenter phase I study combine radiotherapy , cisplatin , twice-weekly gemcitabine , determine recommend dose gemcitabine 25 mg/m² . The objective present study evaluate combination radiotherapy + cisplatin + gemcitabine term disease-free survival non metastatic muscle invasive urothelial cancer patient .</brief_summary>
	<brief_title>A Phase II Trial Evaluating Organ-conserving Strategy Radiochemotherapy Muscle-infiltrative Bladder Cancer</brief_title>
	<detailed_description>If radical cystectomy remain standard care muscle invasive bladder cancer , consequence surgical procedure often harsh . Over past year , concurrent chemo-radiotherapy imposed alternative treatment . Published data concomitant radiochemotherapy ( radiotherapy/cisplatin radiotherapy/cisplatin/5-fluorouracil combination ) show local control rate bladder preservation 5 year range 40 % 65 % accord disease stage , overall survival probability range 40 % 50 % 5 year . In order improve local systemic prognosis , evaluation chemotherapy agent higher radiosensitizing effect , gemcitabine , justified . Gemcitabine possess anti-cancer activity urothelial disease synergetic activity cisplatin . The investigator complete monocenter phase I study combine radiotherapy , cisplatin , twice-weekly gemcitabine , determine recommend dose gemcitabine 25 mg/m² . The objective present study evaluate combination radiotherapy + cisplatin + gemcitabine term disease-free survival non metastatic muscle invasive urothelial cancer patient .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Muscle invasive urothelial cancer ( front line follow progression superficial tumor ) , pT2pT3 stage without lymphatic impairment ( N0 ) without detectable metastasis ( M0 ) . An optimal macroscopic resection ( TURB ) perform The proof invasive tumor muscle bring transurethral resection anaesthesia le 8 week , absence , superficial biopsy formal imaging . Multiples biopsy bladder must also perform . Age ≥ 18 year Life expectancy ≥ 6 month Kanorfsky index ≥ 70 % ( WHO 0 , 1 , 2 ) Biological criterion : neutrophil ≥ 1500/mm3 , Platelets ≥ 100 000/mm3 , haemoglobin ≥ 10 g/dl , creatinine clearance &gt; 60 ml/mn No distant metastasis ( Thorax , abdomen , pelvic CTscan , bone scan ) Efficient contraception premenopausal woman , maintain whole treatment two month completion radiotherapy . No radiotherapy chemotherapy history except situ bladder lesion . No carcinological history except non melanoma skin tumour , situ uterine cervix cancer No contraindication gemcitabine cisplatin . No contraindication radiotherapy Information letter inform consent sign Patient cover social security Bladder tumor without muscle infiltration Epidermoid carcinoma adenocarcinoma Distance metastases extrapelvic node positivity Severe digestive history ( ulcerative colitis , complicate diverticulitis ) Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Organ-conserving strategy</keyword>
	<keyword>Radiochemotherapy</keyword>
	<keyword>non metastatic</keyword>
</DOC>